查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008265

支氣管擴張劑市場：依作用機制、產品類型、適應症、給藥途徑、通路及最終用戶分類－2026-2032年全球市場預測

Bronchodilators Market by Mechanism Of Action, Product Type, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，支氣管擴張劑市場價值將達到 204.2 億美元，到 2026 年將成長至 217.2 億美元，到 2032 年將達到 315.4 億美元，複合年成長率為 6.40%。

主要市場統計數據
基準年（2025 年） 204.2億美元
預計年份（2026年） 217.2億美元
預測年份（2032年） 315.4億美元
複合年成長率 (%) 6.40%

支氣管擴張劑治療概述：重點關注治療基本原則、給藥創新、患者療效以及影響治療策略的醫療保健系統優先事項

支氣管擴張劑仍是阻塞性氣道疾病臨床治療的核心，是緩解症狀、預防病情惡化和維持治療方法的基礎，適用於各種患者族群。過去十年，創新已從分子發現擴展到器械工程、聯合療法和以患者為中心的給藥方案，所有這些都對處方習慣、用藥依從性和健康結果產生影響。

器械創新、聯合治療策略、監管永續性標準和數位健康如何融合，重新定義支氣管擴張劑治療的競爭差異化。

在支氣管擴張劑領域，一場變革正在發生，重塑價值創造和競爭格局，技術、監管和醫療服務等多面向因素的融合推動著這項變革。器材創新是這項變革的關鍵驅動力之一。針對劑量穩定性、易用性和數位化整合進行最佳化的吸入器平台正在改變醫生的處方模式，提高患者的用藥依從性，並最終影響臨床實踐中的療效。

了解與關稅相關的貿易政策轉變對整個支氣管擴張劑供應鏈的採購、製造韌性、價格趨勢和患者獲取的策略性連鎖反應。

貿易政策的變化，例如關稅，會對整個支氣管擴張劑價值鏈產生累積影響，進而影響籌資策略、製造地和商業性經濟效益。在活性成分、吸入器組件和專業契約製造服務地理分散的情況下，關稅帶來的成本壓力可能會促使企業重新評估其供應商組合，尋求近岸外包或加快垂直整合，以保護利潤率並確保供應的連續性。

一種基於實際細分的觀點作用機制、產品類型、適應症、給藥途徑、分銷管道和最終用戶環境與商業化和臨床策略聯繫起來。

精細的細分觀點揭示了每種作用機制、產品類型、適應症、給藥途徑、分銷管道和最終用戶所帶來的不同的商業性、臨床和營運影響。在考慮基於作用機制的治療方法時，相關人員需要區分抗膽鹼能藥物、BETA2促效劑和聯合療法的策略。在抗膽鹼能藥物中，長效和短效亞型在維持治療和搶救治療應用中需要不同的定位；在BETA2促效劑中，長效和短效藥物的預期依從率和劑量也不同。吸入性糖皮質激素與長效BETA2促效劑的聯合用藥，或長效BETA2受體促效劑與長效毒蕈鹼受體拮抗劑的聯合用藥，為簡化治療方法和靶向重疊的病理學通路提供了契機。

影響全球主要地區產品採用、監管合作、報銷方案協調和通路策略的區域趨勢和實施重點。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的治療方法採納、監管路徑和商業性實施具有顯著影響，每個地區都展現出獨特的結構和需求側特徵。在美洲，成熟的支付方框架和廣泛的零售藥房網路正在推動擴充性的產品上市和數位化用藥依從性試點計畫。同時，人們對基於價值的合約的興趣日益濃厚，越來越重視可驗證的健康結果和減少急診護理的使用。

競爭格局分析，重點在於策略聯盟、設備差異化、價格競爭和能力整合，這些因素共同推動了支氣管擴張劑治療領域的長期定位。

支氣管擴張劑市場的競爭動態由眾多公司共同塑造，其中包括成熟的創新製藥企業、專業的吸入器製造商以及靈活的非專利藥和生物類似藥公司，每家公司都發揮自身獨特的優勢來創造臨床和商業性價值。行業領導企業正日益將自身的藥物組合與專有或合作開發的給藥系統相結合，以提高患者的用藥依從性並實現治療差異化。整合數位感測器和數據平台的醫療器材公司正在增強病人參與，並提供真實世界數據以支援與支付方進行價值評估的討論。

高階主管面臨的實際策略挑戰是如何將產品組合、設備、供應彈性、支付方參與和永續性與長期商業性成功相協調。

產業領導企業應採取多管齊下的策略策略，平衡短期商業性挑戰與長期能力建構。首先，應優先最佳化產品組合，使產品特性（例如作用持續時間、聯合治療潛力以及設備易用性）與最相關的臨床領域和醫療環境相符。其次，應投資於設備和數位化整合，以減少使用者操作錯誤，提高用​​藥依從性，並產生有助於與支付方談判和製定臨床指南的真實世界數據。

對用於為相關人員提供檢驗和經過驗證的見解的嚴格混合方法研究途徑、專家檢驗和細分框架進行了描述。

支持這些發現的研究採用了一種結構化、多方面的方法，以確保其穩健性和與實際應用的相關性。主要研究包括對臨床醫生、醫院採購經理、藥屋主任、醫療設備工程師和支付方的訪談，以了解他們對治療效果、醫療設備器材易用性和採購考量等方面的第一手觀點。次要分析則利用監管指南、臨床文獻和上市公司資訊披露，梳理了產品平臺、醫療設備能力和近期戰略交易。

整合策略重點和臨床考慮因素，涵蓋相關人員將治療創新轉化為對患者和醫療保健系統可衡量價值的準備過程。

總之，支氣管擴張劑治療領域仍是一個充滿活力的動態過程，臨床療效、給藥方式創新、監管壓力以及不斷演變的醫療保健模式相互交織。產品開發人員和銷售團隊的成功將越來越取決於他們能否將藥理療效與卓越的設備體驗、供應鏈的適應性以及對支付方和醫療服務提供者俱有吸引力的價值提案相結合。長效和短效藥物之間的相互作用、聯合治療的興起以及給藥途徑的多樣性凸顯了製定與臨床路徑和患者需求相符的精細化市場細分策略的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響（2025 年）

第7章：人工智慧的累積影響（2025 年）

第8章 支氣管擴張劑市場：依作用機制分類

  • 抗膽鹼能藥物
    • 長效毒蕈鹼受體拮抗劑
    • 短效毒蕈鹼受體拮抗劑
  • BETA2促效劑
    • 長效BETA2促效劑
    • 短效BETA2促效劑
  • 組合藥物
    • ICS/LABA組合藥物
    • LABA/LAMA組合藥物

第9章 支氣管擴張劑市場：依產品類型分類

  • 長效型
  • 短效

第10章 支氣管擴張劑市場：依適應症分類

  • 氣喘
  • COPD

第11章 支氣管擴張劑市場：依給藥途徑分類

  • 吸入
    • 乾粉吸入器
    • 定量吸入器
    • 緩霧吸入器
  • 注射藥物
  • 霧化
    • 噴射霧化
    • 超音波霧化
  • 口服

第12章 支氣管擴張劑市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 支氣管擴張劑市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第14章 支氣管擴張劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 支氣管擴張劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 支氣管擴張劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國支氣管擴張劑市場

第18章：中國支氣管擴張劑市場

第19章 競爭情勢

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）
  • AdvaCare Pharma
  • AMGIS Lifescience Ltd.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Cipla Limited
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Prasco Laboratories
  • Ralington Pharma LLP
  • Siemens Healthcare GmbH
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Vectura Group Plc
  • Zydus Group
Product Code: MRR-C002B1C9948B

The Bronchodilators Market was valued at USD 20.42 billion in 2025 and is projected to grow to USD 21.72 billion in 2026, with a CAGR of 6.40%, reaching USD 31.54 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.42 billion
Estimated Year [2026] USD 21.72 billion
Forecast Year [2032] USD 31.54 billion
CAGR (%) 6.40%

Contextual overview of bronchodilator therapies highlighting therapeutic fundamentals, delivery innovation, patient outcomes, and health system priorities shaping treatment strategies

Bronchodilators remain central to the clinical management of obstructive airway diseases, serving as foundational therapies for symptom relief, exacerbation prevention, and maintenance care across diverse patient populations. Over the past decade, innovation has shifted beyond molecule discovery to encompass device engineering, combination pharmacotherapies, and patient-centric delivery solutions that collectively influence prescribing practices, adherence, and health outcomes.

As care models evolve, the role of bronchodilators intersects with broader health system priorities such as reducing hospitalizations, improving chronic disease management in ambulatory and home settings, and meeting environmental and regulatory targets related to inhaler propellants and device lifecycle. Consequently, stakeholders must evaluate therapeutic differentiation not only on pharmacology but also on the total value proposition that includes device usability, digital adherence support, supply chain reliability, and payer alignment. This introduction frames the subsequent analysis by emphasizing these multi-dimensional pressures and opportunities shaping product strategy and commercial execution.

How device innovation, combination therapeutic strategies, regulatory sustainability standards, and digital health are converging to redefine competitive differentiation in bronchodilator care

The bronchodilator landscape is experiencing transformative shifts driven by converging forces in technology, regulation, and care delivery that are reshaping value creation and competitive positioning. Device innovation is one primary axis of change: inhaler platforms optimized for dose consistency, reduced coordination requirements, and digital integration are changing physician prescribing patterns and enhancing patient adherence, which in turn affects real-world effectiveness.

Simultaneously, therapeutic strategy is moving toward integrated solutions that combine bronchodilation with anti-inflammatory or dual-mechanism approaches to simplify regimens and target diverse phenotypes. Regulatory emphasis on environmental impact has accelerated transitions away from traditional propellants and encouraged manufacturers to redesign products with sustainability in mind. At the same time, digital health and remote monitoring are enabling new adherence interventions and data-driven care pathways, while supply chain resilience and manufacturing flexibility have become strategic priorities following recent global disruptions. Altogether, these shifts create both entry hurdles and opportunities for differentiation across product life cycles.

Understanding the strategic ripple effects of tariff-related trade policy shifts on sourcing, manufacturing resilience, pricing dynamics, and patient access across the bronchodilator supply chain

Trade policy changes such as tariffs can exert a cumulative impact across the bronchodilator value chain, influencing sourcing strategies, manufacturing footprints, and commercial economics. In an environment where active pharmaceutical ingredients, inhaler components, and specialized contract manufacturing services are globally distributed, tariff-driven cost pressures can prompt firms to re-evaluate supplier portfolios, pursue nearshoring, or accelerate vertical integration to protect margins and ensure supply continuity.

These adjustments often cascade into pricing negotiations with payers, procurement decisions by large health systems, and contracting strategies across distribution channels. Over time, companies that proactively diversify supply nodes, invest in regional manufacturing capacity, and design adaptable sourcing frameworks are better positioned to mitigate tariff volatility. Moreover, sustained policy uncertainty incentivizes strategic collaborations, long-term supplier agreements, and inventory management approaches that balance cost, lead time, and regulatory compliance to preserve patient access and commercial stability.

Actionable segmentation-driven perspectives connecting mechanisms, product types, indications, administration routes, channels, and end-user settings to commercialization and clinical strategies

A nuanced segmentation lens reveals distinct commercial, clinical, and operational implications across mechanisms, product types, indications, routes, distribution channels, and end users. When therapies are considered by mechanism of action, stakeholders must differentiate strategies for anticholinergics, beta-2 agonists, and combination agents; within anticholinergics the long-acting and short-acting subtypes demand different positioning around maintenance versus rescue use, while within beta-2 agonists long-acting and short-acting agents carry divergent adherence profiles and dosing expectations. Combination agents that pair inhaled corticosteroids with long-acting beta-2 agonists or combine long-acting beta-2 agonists with long-acting muscarinic antagonists create opportunities to streamline regimens and target overlapping pathophysiologic pathways.

Product type segmentation into long-acting and short-acting agents carries commercial consequences for life-cycle management, patient education, and formulary negotiation. Indication-driven strategies must recognize the heterogeneous needs of asthma versus COPD populations, where disease trajectory, comorbidity profiles, and inhaler training requirements differ substantially. Route of administration preferences-from inhalation delivered via dry powder inhaler, metered-dose inhaler, or soft mist inhaler to injectable, nebulized (jet versus ultrasonic), and oral formulations-shape delivery challenges, adherence behaviors, and site-of-care decisions. Distribution channel dynamics spanning hospital pharmacy, online pharmacy, and retail pharmacy require tailored supply, patient support, and reimbursement engagement. Finally, end-user settings including clinics, home care, and hospitals alter demand reliability, device selection criteria, and the importance of caregiver training, reinforcing that segmentation must inform targeted product development and commercialization plans rather than serve as a one-size-fits-all framework.

Comparative regional dynamics and execution priorities that influence product adoption, regulatory interaction, reimbursement alignment, and channel strategies across major global regions

Regional dynamics materially shape therapeutic adoption, regulatory pathways, and commercial execution across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting distinct structural and demand-side characteristics. In the Americas, established payer frameworks and widespread retail pharmacy networks favor scalable product launches and digital adherence pilots, while growing interest in value-based contracting increasingly rewards demonstrable health outcomes and reductions in acute care utilization.

Europe, the Middle East & Africa present a heterogeneous regulatory and reimbursement landscape where harmonization across major European regulatory authorities coexists with variable access in emerging markets; in these contexts, demonstrating cost-effectiveness and aligning with national health priorities often determines formulary acceptance. Asia-Pacific combines rapidly aging populations and high urbanization with diverse healthcare systems, creating opportunities for both premium device adoption in well-resourced markets and cost-sensitive solutions in lower-resource settings. Cross-regionally, environmental policy, disease burden driven by air quality, and the pace of digital health adoption influence product design priorities and go-to-market sequencing, requiring bespoke strategies that reflect local care pathways and procurement behaviors.

Competitive landscape analysis emphasizing strategic alliances, device differentiation, pricing competition, and capability consolidation driving long-term positioning in bronchodilator care

Competitive dynamics in bronchodilators are defined by a mix of incumbent pharmaceutical innovators, specialist inhaler manufacturers, and agile generic and biosimilar players, each leveraging distinct assets to capture clinical and commercial value. Industry leaders are increasingly pairing pharmacologic portfolios with proprietary or co-developed delivery systems to enhance adherence and lock in therapeutic differentiation. Device companies that integrate digital sensors and data platforms strengthen patient engagement and provide real-world evidence that supports value discussions with payers.

Meanwhile, generic manufacturers compete on cost-efficiency and manufacturing scale, often securing critical access channels through established wholesaler relationships and competitive tendering. Strategic partnerships and licensing arrangements between drug developers and device specialists accelerate time-to-market for combination solutions, while selective mergers and acquisitions sustain consolidation aimed at optimizing supply chains and securing technical capabilities. For companies operating in this space, success depends on aligning R&D investments, commercial capabilities, and stakeholder engagement to deliver demonstrable improvements in clinical outcomes, patient experience, and total cost of care.

Practical strategic imperatives for executives to align portfolios, devices, supply resilience, payer engagement, and sustainability with long-term commercial success

Industry leaders should adopt a multi-pronged strategic playbook that balances near-term commercial imperatives with long-term capability building. First, prioritize portfolio optimization that aligns product attributes-duration of action, combination therapy potential, and device usability-with the most pertinent clinical segments and care settings. Second, invest in device and digital integrations that reduce user error, support adherence, and generate real-world evidence to inform payer negotiations and clinical guidelines.

Third, strengthen supply chain resilience through supplier diversification, regional manufacturing options, and strategic inventory management to mitigate trade policy or disruption risks. Fourth, engage proactively with payers and health systems to design value-based arrangements that reward clinically meaningful outcomes and cost reductions. Fifth, tailor market access and launch strategies by region, recognizing that regulatory pathways, procurement norms, and patient preferences vary substantially. Finally, embed sustainability and lifecycle planning into product design to address environmental mandates and to increasingly resonate with institutional purchasers and end users. Implementing these recommendations will require cross-functional governance and clear metrics to track progress and adjust tactics as conditions evolve.

Description of the rigorous mixed-methods research approach, expert validation, and segmentation framework used to derive practical and validated insights for stakeholders

The research underpinning these insights combines a structured, multi-source approach to ensure robustness and real-world relevance. Primary research comprised interviews with clinicians, hospital procurement leads, pharmacy directors, device engineers, and payers to capture frontline perspectives on therapeutic performance, device usability, and procurement considerations. Secondary analysis drew on regulatory guidance, clinical literature, and public company disclosures to map product pipelines, device capabilities, and recent strategic transactions.

Data synthesis applied triangulation across qualitative inputs and documentary evidence to validate themes and identify divergences. Segmentation analysis used mechanistic, product, indication, route, distribution, and end-user lenses to create actionable slices for commercial strategy. Limitations include variability in regional data transparency and the evolving nature of regulatory and trade policy landscapes; where uncertainty exists, scenario-based interpretation has been used to describe implications rather than to predict discrete outcomes. Validation workshops with external clinical and commercial experts further refined the findings and bolstered reliability for decision-makers.

Synthesis of strategic priorities and clinical considerations that encapsulate readiness pathways for stakeholders to convert therapeutic innovation into measurable patient and system value

In conclusion, bronchodilator therapy remains a dynamic field where clinical efficacy intersects with delivery innovation, regulatory pressures, and evolving care models. Success for product developers and commercial teams will increasingly depend on the ability to integrate pharmacologic strength with superior device experience, supply chain adaptability, and compelling value propositions for payers and providers. The interplay between long-acting and short-acting agents, the rise of combination therapies, and the diversity of administration routes underscore the need for finely tuned segmentation strategies that align with clinical pathways and patient needs.

Looking ahead, organizations that proactively invest in device-digital ecosystems, diversify sourcing strategies, and engage payers with outcomes-focused evidence will be best positioned to translate scientific advances into measurable improvements in patient care. Strategic patience paired with operational agility will be essential as policy, environmental, and technological currents continue to reshape the competitive terrain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bronchodilators Market, by Mechanism Of Action

  • 8.1. Anticholinergics
    • 8.1.1. Long-Acting Muscarinic Antagonists
    • 8.1.2. Short-Acting Muscarinic Antagonists
  • 8.2. Beta-2 Agonists
    • 8.2.1. Long-Acting Beta-2 Agonists
    • 8.2.2. Short-Acting Beta-2 Agonists
  • 8.3. Combination Agents
    • 8.3.1. ICS/LABA Combinations
    • 8.3.2. LABA/LAMA Combinations

9. Bronchodilators Market, by Product Type

  • 9.1. Long-Acting
  • 9.2. Short-Acting

10. Bronchodilators Market, by Indication

  • 10.1. Asthma
  • 10.2. COPD

11. Bronchodilators Market, by Route Of Administration

  • 11.1. Inhalation
    • 11.1.1. Dry Powder Inhaler
    • 11.1.2. Metered-Dose Inhaler
    • 11.1.3. Soft Mist Inhaler
  • 11.2. Injectable
  • 11.3. Nebulization
    • 11.3.1. Jet Nebulization
    • 11.3.2. Ultrasonic Nebulization
  • 11.4. Oral

12. Bronchodilators Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Bronchodilators Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals

14. Bronchodilators Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Bronchodilators Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Bronchodilators Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Bronchodilators Market

18. China Bronchodilators Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AdvaCare Pharma
  • 19.6. AMGIS Lifescience Ltd.
  • 19.7. AstraZeneca PLC
  • 19.8. Boehringer Ingelheim International GmbH
  • 19.9. Cambrex Corporation
  • 19.10. Catalent, Inc.
  • 19.11. Cipla Limited
  • 19.12. GlaxoSmithKline Plc
  • 19.13. Glenmark Pharmaceuticals Limited
  • 19.14. Hikma Pharmaceuticals PLC
  • 19.15. Lupin Limited
  • 19.16. Mylan Inc. by Viatris Inc.
  • 19.17. Nephron Pharmaceuticals Corporation
  • 19.18. Novartis AG
  • 19.19. Perrigo Company PLC
  • 19.20. Pfizer Inc.
  • 19.21. Prasco Laboratories
  • 19.22. Ralington Pharma LLP
  • 19.23. Siemens Healthcare GmbH
  • 19.24. Steris Healthcare Pvt. Ltd.
  • 19.25. Sun Pharmaceutical Industries Limited
  • 19.26. Teva Pharmaceutical Industries Ltd.
  • 19.27. Thermo Fisher Scientific Inc.
  • 19.28. Vectura Group Plc
  • 19.29. Zydus Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRONCHODILATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRONCHODILATORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRONCHODILATORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHODILATORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRONCHODILATORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRONCHODILATORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BRONCHODILATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BRONCHODILATORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRONCHODILATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRONCHODILATORS MARKET SIZE, BY LONG-ACTING MUSCARINIC ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHODILATORS MARKET SIZE, BY LONG-ACTING MUSCARINIC ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHODILATORS MARKET SIZE, BY LONG-ACTING MUSCARINIC ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHODILATORS MARKET SIZE, BY SHORT-ACTING MUSCARINIC ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHODILATORS MARKET SIZE, BY SHORT-ACTING MUSCARINIC ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHODILATORS MARKET SIZE, BY SHORT-ACTING MUSCARINIC ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHODILATORS MARKET SIZE, BY LONG-ACTING BETA-2 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHODILATORS MARKET SIZE, BY LONG-ACTING BETA-2 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHODILATORS MARKET SIZE, BY LONG-ACTING BETA-2 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHODILATORS MARKET SIZE, BY SHORT-ACTING BETA-2 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHODILATORS MARKET SIZE, BY SHORT-ACTING BETA-2 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHODILATORS MARKET SIZE, BY SHORT-ACTING BETA-2 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHODILATORS MARKET SIZE, BY ICS/LABA COMBINATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHODILATORS MARKET SIZE, BY ICS/LABA COMBINATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHODILATORS MARKET SIZE, BY ICS/LABA COMBINATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHODILATORS MARKET SIZE, BY LABA/LAMA COMBINATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHODILATORS MARKET SIZE, BY LABA/LAMA COMBINATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHODILATORS MARKET SIZE, BY LABA/LAMA COMBINATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHODILATORS MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHODILATORS MARKET SIZE, BY LONG-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHODILATORS MARKET SIZE, BY LONG-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHODILATORS MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHODILATORS MARKET SIZE, BY SHORT-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHODILATORS MARKET SIZE, BY SHORT-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHODILATORS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHODILATORS MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHODILATORS MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHODILATORS MARKET SIZE, BY COPD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRONCHODILATORS MARKET SIZE, BY COPD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRONCHODILATORS MARKET SIZE, BY COPD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHODILATORS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHODILATORS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRONCHODILATORS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRONCHODILATORS MARKET SIZE, BY METERED-DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRONCHODILATORS MARKET SIZE, BY METERED-DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRONCHODILATORS MARKET SIZE, BY METERED-DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRONCHODILATORS MARKET SIZE, BY SOFT MIST INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRONCHODILATORS MARKET SIZE, BY SOFT MIST INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRONCHODILATORS MARKET SIZE, BY SOFT MIST INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRONCHODILATORS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRONCHODILATORS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRONCHODILATORS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRONCHODILATORS MARKET SIZE, BY JET NEBULIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRONCHODILATORS MARKET SIZE, BY JET NEBULIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRONCHODILATORS MARKET SIZE, BY JET NEBULIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRONCHODILATORS MARKET SIZE, BY ULTRASONIC NEBULIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRONCHODILATORS MARKET SIZE, BY ULTRASONIC NEBULIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRONCHODILATORS MARKET SIZE, BY ULTRASONIC NEBULIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRONCHODILATORS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRONCHODILATORS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRONCHODILATORS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRONCHODILATORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRONCHODILATORS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRONCHODILATORS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRONCHODILATORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRONCHODILATORS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRONCHODILATORS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRONCHODILATORS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRONCHODILATORS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRONCHODILATORS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS BRONCHODILATORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL BRONCHODILATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GCC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GCC BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 211. GCC BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 212. GCC BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. GCC BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. GCC BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 217. GCC BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. GCC BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. G7 BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. G7 BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 245. G7 BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. G7 BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. G7 BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. G7 BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 253. G7 BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. G7 BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. NATO BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. NATO BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 257. NATO BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. NATO BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. NATO BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. NATO BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 264. NATO BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 265. NATO BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. NATO BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES BRONCHODILATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA BRONCHODILATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA BRONCHODILATORS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA BRONCHODILATORS MARKET SIZE, BY BETA-2 AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA BRONCHODILATORS MARKET SIZE, BY COMBINATION AGENTS, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA BRONCHODILATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA BRONCHODILATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA BRONCHODILATORS MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA BRONCHODILATORS MARKET SIZE, BY NEBULIZATION, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA BRONCHODILATORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA BRONCHODILATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)